Relay Therapeutics (NASDAQ: RLAY) revenue
Relay Therapeutics reported revenue of $15.4m for fiscal 2025, 53.4% more than in fiscal 2024 ($10.0m). Since fiscal 2020 its revenue has fallen by 81.4%, an average decline of 28.6% a year.
Relay Therapeutics's best year of the last 6 was fiscal 2020. The biggest drop was in fiscal 2021, −96.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $15.4m | +53.4% | −$302.7m | −1,971.6% |
| 2024 | $10.0m | −60.8% | −$372.5m | −3,722.1% |
| 2023 | $25.5m | +1,749.8% | −$373.0m | −1,460.1% |
| 2022 | $1.4m | −54.4% | −$299.3m | −21,670.9% |
| 2021 | $3.0m | −96.3% | −$364.7m | −12,040.2% |
| 2020 | $82.7m | — | −$55.8m | −67.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Relay Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Relay Therapeutics ranks 358th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Relay Therapeutics, 53.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 356th | Omniab | $18.7m | −29.3% |
| 357th | Dianthus Therapeutics | $16.1m | −7.2% |
| 358th | Relay Therapeutics | $15.4m | 53.4% |
| 359th | Lineage Cell Therapeutics | $14.6m | 53.2% |
| 360th | Opus Genetics | $14.2m | 29.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Relay Therapeutics
- How much revenue did Relay Therapeutics make in fiscal 2025?
- Relay Therapeutics reported revenue of $15.4m for fiscal 2025, compared with $10.0m in fiscal 2024.
- How much has the revenue of Relay Therapeutics fallen?
- Between fiscal 2020 and fiscal 2025 it went from $82.7m to $15.4m: 81.4% less, an average decline of 28.6% a year.
- What was the best year for revenue at Relay Therapeutics?
- Of its last 6 fiscal years, fiscal 2020, with $82.7m.
- Where does Relay Therapeutics rank in its sector by revenue?
- It ranks 358th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Relay Therapeutics come from?
- From the annual report (Form 10-K) that Relay Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Relay Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Relay Therapeutics: the Relay Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.